WASHINGTON – After expressing frustration at the slow approval of treatments for the coronavirus, el presidente Donald Trumpauthorized this Sunday the use of plasma for patients with Covid-19.
The announcement came after White House representatives suggested that the Food and Drug Administration (FDA) had politically motivated delays in the approval of a vaccine for the disease. This was changing the chances of Trump’s re-election.
On the eve of the Republican National Convention, Trump issued the emergency order that will make it easier for some patients to get treatment.
He blood plasma, taken from patients who have recovered from the coronavirus and rich in antibodies, may provide benefits to those who fight the disease. But the evidence has not been conclusive as to how it works or how best to manage it.
It was not immediately clear what the impact of this decision would be.
“In the independent judgment of experts and expert scientists at FDA …
#COVID19
convalescent plasma is safe and shows promising efficacy thereby meeting the criteria for an emergency use authorization.” — FDA Commissionerpic.twitter.com/7jVsbcujMJ
&- U.S. FDA (@US_FDA)
–
The agency also said it found this to be a safe approach in an analysis of 20,000 patients who received this treatment. Until now, 70,000 patients have been treated with blood plasma, the FDA specified.
The patients who benefited the most from this treatment were those under the age of 80 who were not wearing a respirator, the agency said. Those patients had a 35 percent better survival rate one month after receiving treatment.
In this context, the White House refused to comment on a newspaper report Financial Times which stated that the Trump administration is considering speed up an experimental vaccine for Covid-19 that AstraZeneca and the University of Oxford are working on, for use in the United States prior to the November 3 presidential election.
ANSA and DPA agencies
ALSO
– .
